MURRAY N. EHRINPREIS, M.D. OFFICE Division of Gastroenterology Harper Hospital 3990 John R Detroit, Michigan 48201 Telephone: (313) 745-8601 EDUCATION: 1964 - 1968 BA Degree, University of Michigan, Ann Arbor, MI 1968 - 1972 MD Degree, New York University School of Medicine, New York, NY TRAINING: 1972 - 1973 Medical Intern, Bronx Municipal Hospital Center, Bronx, NY 1973 - 1975 Medical Resident, Bronx Municipal Hospital Center, Bronx, NY 1975 - 1977 Fellow in Gastroenterology, Albert Einstein College of Medicine,

Bronx, NY FACULTY APPOINTMENTS: 1977 - 1990 Assistant Professor of Medicine, Division of Gastroenterology,

Wayne State University School of Medicine, Detroit, MI 1978 - 1979 Acting Chief, Division of Gastroenterology, Wayne State University

School of Medicine, Detroit, MI 1987 – 2000 Director of Clinical Education, Division of Gastroenterology, Wayne

State University School of Medicine, Detroit, MI 2000 - present Fellowship Director, Division of Gastroenterology, Wayne State

University School of Medicine, Detroit, MI 1990 - 2000 Associate Professor (Clinician-Educator) of Medicine, Division of

Gastroenterology, Wayne State University School of Medicine, Detroit, MI

2000 - present Professor (Clinician-Educator) of Medicine, Division of

Gastroenterology, Wayne State University School of Medicine, Detroit, MI

2HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS: 1983 – 2002 Director of Nutritional Support Services, Harper-Grace Hospitals, Harper

Division, Detroit, MI 1978 - 1979 Interim Chief, Section of Gastroenterology Harper-Grace 1990 - 1991 Hospitals, Detroit, MI 1990 - 1991 Interim Director, Division of Gastroenterology, Wayne State

University School of Medicine, Detroit, Michigan MAJOR PROFESSIONAL SOCIETIES: American Association for the Study of Liver Disease American Federation for Clinical Research American Gastroenterological Association American Society for Parenteral and Enteral Nutrition American College of Gastroenterology, Fellow; Board of Governors Member from MI 1992-1998; Ad Hoc Committee on Training 2003 American Society for Gastrointestinal Endoscopy Midwest Gut Club Detroit Gastroenterological Society; President 1985-1986 Michigan Society for Gastrointestinal Endoscopy; Secretary-Treasurer 1992-1994; President 1996-1998; Board Member 1992-1999 Michigan Society for Parenteral and Enteral Nutrition, Program Committee LICENSURE & BOARD CERTIFICATION: Licensure - Michigan 1975 - Diplomate, American Board of Internal Medicine 1977 - Diplomate, American Board of Gastroenterology HONORS AND AWARDS: Phi Beta Kappa - University of Michigan College Teaching Award - Wayne State University, 1998 College Teaching Award – Wayne State University, 2001 SERVICE: Patient Care: Active Attending and consulting gastroenterology practice with University Internal Medicine Specialists in the Harper Professional Bldg., Harper University Hospital and Detroit Receiving Hospital. Active GI endoscopic practice. Outpatient total parenteral nutrition management.

3Professional Consultation: Public Media Presentation (TV) Health Matters, Channel 56, "Beating

Digestive Disorders", February 17, 1994. Public Media Presentation (Radio) WWJ, “Hepatitis”, February 1997. Interview on “Gastroesophageal Reflux Disease” in Michigan

Chronicle, February 2001. Interview on “Capsule Endoscopy” on the Dr. Jimmy Womack

Show, WGPR (Radio), December 5, 2004. 1985 - Present Presentations to local and regional bodies (See Presentations). 1977 - present Gastroenterology Consultation Attending, Harper Hospital (3 - 4

months per year) 1977 - present Gastroenterology Consultation Attending, Detroit Receiving

Hospital, (3 - 4 months) 1977 - present Gastroenterology Consultant, Grace Hospital 1977 - present Gastroenterology Consultant, Detroit Rehabilitation Institute 1977 – 1998 Gastroenterology Consultant, Veterans Affairs Medical Center, Allen

Park and Detroit 1979 - present Medical Nutritional Support Services Attending, Harper Hospital

(4 months per year) Editorial Activity: Reviewer American Journal of Gastroenterology Reviewer Gastroenterology Reviewer New England Journal of Medicine Book Reviewer New England Journal of Medicine Reviewer Journal of Clinical Outcomes Management Reviewer Journal of the Neurological Sciences Reviewer American Journal of the Medical Sciences Reviewer Drugs (Adis Drug Evaluation)

4SERVICE (Cont.): Boards & Committees (Also see Professional Societies) Medical School Committees: 1996 - 1997 Wayne State University School of Medicine, Department of

Biochemistry Internal Review Committee Departmental Committees: 1984 - 1991 Treasurer, Board of Trustees, University Internists, P.C., (School of

Medicine Clinical Practice Group) 1984 DMCIOAD Board of Trustees 1984 - 1985 Liaison Committee for Medical Education 1987 Ad Hoc Department of Internal Medicine Internal Review Committee

(Reviewer - Practice Plan) 1991 - 1995 Operations Committee, Affiliated Internists (Dept. of Medicine Clinical

Practice Group) 1992 - present Risk Management Committee, Affiliated Internists 1993 – 1997 Merit and Compensation Committee, Affiliated Internists 1996 – 1998 Board of Directors, Affiliated Internists 2000 - present Protected Time Committee 2001- present Research Committee 2001- 2004 Compliance Committee 2002- present Merit and Compensation Committee 2003-present Residency Operations Committee 2004-present Ambulatory Practice Advisory Committee

5Hospital Committees: 1983 - 1984 Medical Advisory Board, Harper-Grace Hospitals 1980 - 1985 Nutrition Committee, Harper Hospital 1979 - 1986 Quality Assurance Committee, Harper Hospital 2001- 2003 Medical Advisory Board, Harper University Hospital 1979 - present Endoscopy Committee, Harper Hospital (Chairman,

1986-present) 1989 - present Harper-Grace-Hutzel Diet Manual Committee, Chairman 1991 - present Nutrition Advisory Committee, Harper Hospital, Chairman 1993 - present Quality Enhancement and Clinical Resource Management

Committee 2000 - present Chairman, Board of Trustees, Harper Medical Staff Trust Fund TEACHING: Wayne State University Faculty since 1977 1977 - 1998 Medicine Attending, Wayne State University School of Medicine,

Department of Medicine (1 - 4 months per year) 1978 - 1991 Coordinator, Weekly Gastroenterology Clinical Conference

(Continuing Medical Education Accredited) 1978 - 1991 Coordinator, Weekly Gastroenterology Basic Science Conference

(Continuing Medical Education Accredited) 1978 - present Clinical Coordinator, Year I GI Physiology 1978 - 1988 Lecturer Year I GI Physiology 1984 - present Coordinator, Year II GI Pathophysiology Course 1978 - present Lecturer, Year II GI Pathophysiology Course 1978 - present Coordinator, Year III GI Teaching Program 1978 – 1997 Lecturer, Year III GI Teaching Program (quarterly) 1983 - 1991 Coordinator, Weekly GI Journal Club

61984 - 1990 Attending, GI Medical Subspecialty Rotation, Wayne State

University School of Medicine - Harper Hospital (2 - 3 months per year)

1986 – 2000 Director of Clinical Education, Division of Gastroenterology, Wayne

State University 1986 - 1988 Lecturer, Wayne State University Dept. of Medicine Board Review

Course 1987 – 1998 Lecturer, Wayne State University School of Pharmacy, Pharm D

Students 1989 - present Medicine Residency Curriculum Committee, Wayne State

University 1996 - present Lecturer and GI Course Coordinator, Wayne State University

Physicians Assistant Training Program 2003 - present Lecturer, Wayne State University Year I Physiology 2005-present Lecturer, Wayne State University, Graduate Students and Nurse

Clinicians Pathophysiology GRANT SUPPORT: 1983 Ortho Pharmaceutical Corporation, "Effect of Etintidine in the Short-Term

Treatment of Duodenal Ulcer Disease Protocol # C82-061/062. 7/83-7/85. Funded for $10,500. Principal Investigator.

1987 NIH CA 45831 "Inheritance and Markers of Colorectal Cancer and Polyps"

5/87-4/90. Funded for $200,285/$711,771. Co-investigator. 1992 Alpha I Biomedicals, Inc., "Thymosin Alpha 1 Treatment of Type B Virus

Chronic Hepatitis." 9/1/90 -10/1/94. Funded for $608,000. Co-Investigator. 1993 Amgen Inc., "A Phase III, Randomized, Double-Blind Controlled Trial of

Recombinant Methionyl Interferon Consensus in Patients with Chronic Hepatitis C Virus (HCV) Infection," 2/1/93 - 4/30/95. Funded for $142,750. Principal Investigator.

1994 Amgen Inc., "A Phase III, Open-Labeled, Randomized, Multicenter Trial to

Determine the Efficacy of Recombinent-Methionyl Interferon-Consensus in Patients with Chronic Hepatitis C Virus after Prior Treatment with r-met IFN-Con1, or Interferon alfa-2B recombinent," 9/1/94 - 9/30/99. Funded for $107, 419. Principal Investigator.

1997 - 1999 Schering-Plough Integrated Therapeutics Group, Inc. Intron A + Ribavirin for

treatment of patients with Interferon/Refractory or Interferon/Relapsed chronic hepatitis C. R96-419. $75,000. Co-Principal Investigator.

71998 - 1999 Schering-Plough Integrated Therapeutics Group, Inc. Health-Related

Quality of Life Questionnaire for Patients with Chronic Hepatitis C Who do not qualify for combination study. R97-023. $75,000. Co-Principal Investigator.

1998 - 2000 Schering-Plough Integrated Therapeutics Group, Inc. Intron A Induction

Protocol for Treatment of patients with chronic hepatitis C Who do not qualify for combination study. R97-023. $75,000. Co-Principal Investigator.

1998 - 2000 Schering-Plough Integrated Therapeutics Group, Inc. Intron A + Ribavirin for

treatment of patients with chronic hepatitis C not previously treated with Interferon. R97-024. $75,000. Co-Principal Investigator.

1998-2000 Amgen Inc. Consensus interferon (Infergen) treatment of chronic hepatitis C patients who failed interferon/ribavirin therapy. Funded for $25,000. Co-investigator.

1998-2003 Department of Veterans Affairs (VA Merit Review), Principal Investigators:

Adhip N. Majumdar, Ph.D, D.Sc. and Richard Jaszewski, M.D. Co-Investigator: Murray Ehrinpreis, M.D., Title: Colorectal Adenoma: Chemoprevention by Folic Acid. $625,000 (Direct Cost). Score:20.7

2000-2007 Schering-Plough Integrated Therapeutics Group, Inc. Phase II study of

long term PEG Intron for patients who have failed to respond to Rebetron/Interferon with advanced fibrosis and cirrhosis secondary to hepatitis C. Funded for $30,000. Co-investigator.

PUBLICATIONS Original Observations in Refereed Journals: 1. Kreitzer S, Ehrinpreis M, Miguel E, and Petrasek J: Acute myoglobinuric renal

failure in polymyositis. NY State J Med 295-297, February 1978. 2. Diazdeleon L, Ehrinpreis MN, Kershenobich D, and Rojkind M: Liver injury and

liver fibrogenesis, Metabolic Effects of Alcohol, (Developments in Nutrition and Metabolism), vol l, (P Avogaro, CR Sirtori, E Tromoli, eds). Elsevier/North Holland Biomedical Press, Amsterdam, 1979, pp 269-280.

3. Ehrinpreis M, Giambrone M-A, and Rojkind M: Liver proline oxidase activity and

collagen synthesis in rats with cirrhosis induced by CCl4. Biochim Biophys Acta 629:184-193, 1980.

4. Weinstock JV, Boros DL, Ehrinpreis MN, and Gee JB: The effect of SQ 14225, an

inhibitor of angiotensin I converting enzyme on the granulomatous response to schistosoma mansoni in mice. J Clin Invest 67:93l-936, 1981.

5. Cid AA, Pietruk T, Bidari CZ, and Ehrinpreis MN: Cecal fecaloma mimicking

colonic neoplasm. Dig Dis Sci 26:1134-1137, 1981.

8 6. Beisel KW, Ehrinpreis MN, Bhathal PS, MacKay IR, and Rose NR: Genetics of

carbon tetrachloride-induced liver injury in mice. II. H-2 and non-H-2 control. Br J of Exp Path 65:125-131,1984.

7. Marcuard S, Ehrinpreis MN, and Fitter W: Gold-induced ulcerative proctitis:

Report and review of the literature. J Rheum 14 (1): 142-144, 1987. 8. Luk GD, Moshier JA, and Ehrinpreis MN: Ornithine Decarboxylase as a Marker for

Colorectal Polyps and Cancer. Prog Clin Biol Res 279:227-39,1988. 9. Ehrinpreis MN, Dhar R, and Narula A: Cimetidine-induced galactorrhea. Am Jour

Gastroenterol 84:563-565, 1989. 10. Gupta TP and Ehrinpreis MN: Candida-associated diarrhea. Gastroenterology

98:780-785, 1990. 11. Jaszewski R, Tolia V, Ehrinpreis M, Bodzin J, Peleman R, Korlipara R, and

Weinstock JV: Colonic Mucosal levels of angiotension I and II distinguish Crohn's colitis from ulcerative colitis. Gastroenterology 98:1543-1548, 1990. 12. Desai TK, Maliakkal JB, Kinzie JL, Ehrinpreis MN, Luk GD, and Cehja J: Taurine

depletion after intensive chemotherapy/radiation. Am J Clin Nutr 55:708-11, 1992. 13. Barbish A and Ehrinpreis MN: Successful endoscopic injection sclerotherapy of a

bleeding duodenal varix and review of the literature. Am J Gastroenterol 88:90-92, 1993.

14. Meyerson S, Desai TK, Polidori G, Raval MFT, and Ehrinpreis MN: A case of

intussusception and lymphoid hyperplasia in a patient with AIDS. Am J Gastroenterol 88:303-306, 1993.

15. Meyerson S, Holtz T, Ehrinpreis MN, and Dhar R: Small bowel obstruction during

pregnancy. Am J Gastroenterol 90:299-302, 1995. 16. Alloju M and Ehrinpreis M: Shortage of intravenous multivitamin solution in the

United States (Brief case report, letter). N Eng J Med 337:54, 1997. 17. Tong M, Reddy KR, Lee W, Pockros PJ, Hoefs JC, Ehrinpreis M, et al. Treatment

of chronic hepatitis C with consensus Interferon: A multicenter, randomized, controlled trial. Hepatology 1997;26:747-754.

18. Keeffe EB, Hollinger FB, Ehrinpreis M, et al. Therapy of hepatitis C: consensus

Interferon trials. Hepatology 1997;26,suppl:101S-107S. 19. Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG,

Witt K, Blatt LM, Ehrinpreis MN, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27, 1136-1143.

9 20. Nathani MG, Mutchnick MG, Tynes DJ, Ehrinpreis MN. An unusual case of

amoxicillin/clavulanic acid-related hepatotoxicity. Am J Gastroenterol 1998;93:1363-1365.

21. Lee WM, Reddy KR, Tong MJ, Black M, van Leeuwen DJ, Hollinger, FB, Mullen

KD, Pimstone N, Albert D, Gardner S, Ehrinpreis MN, et al. Early Hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology 1998;28:1411-1415.

22. Zagnoon A, Ehrinpreis MN: Impacted Pigment Gallstone. Gastrointest.

Endoscopy 1999; 49:626. 23. Bonkovsky HL, Woolley JM, Ehrinpreis MN, et al. Reduction of health-related

quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999; 29:264-270.

24. Everson GT, Jensen DM, Craig JR, VanLeeuwen DJ, Bain VG, Ehrinpreis MN, et

al: Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics or nonfibrotics. Hepatology 1999; 30:271-276.

25. Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appelman HD, Peleman

RR, Silva M, Roach KC, Simmons F, Milstein S, Gordon SC, Ehrinpreis MN, : Thymosin - ά, treatment of chronic hepatitis B: results of a phase III multicenter, randomized, double-blind and placebo - controlled study. J. Viral Hep. 1999; 6:397- 403.

26. Xiao Z-Q, Yu Y, Khan A, Jaszewski R, Ehrinpreis MN, Majumdar APM: Induction of

G1 checkpoint in the gastric mucosa of aged rats. Am. J. Physiol. Gastrointest./Liver physiol. 1999; 277 (Gastroentest Liver Physiol 40; G929-G934.

27. Reddy RK, Hoofnagle JH, Tong JM, Lee WM, Pockros, E, Heathcote J, Albert D,

Joh T, Ehrinpreis MN, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30: 787-793.

28. Keeffe EB, Dusheiko GM, Tong MJ, Hollinger FB, Heathcote EJ, McHutchison J,

Albert D, Ehrinpreis MN, et al. Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Cytokines Cell Mol Ther 1999; 5: 211-6.

29. Keefe EB, Dusheiko GM, James SP, Mullen KD, Everson GT, Pimstone NR,

Donovan J, Albert D, Ehrinpreis MN, et al. Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Cytokines Cell Mol Ther 1999; 5: 207-10.

30. McHutchison JG, Blatt LM, deMedina M, Craig JR, Conrad A, Schiff ER,

Tong MJ, Ehrinpreis MN, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. J Gastroenterol Hepatol 2000; 15: 945-51.

1031. Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M.

Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with PCR-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001; 96: 858-63.

. 32. Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, Turner

JR, Janisse JJ, Massanari M, Mutchnick MG. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001; 8: 264-9.

33. Ullah N, Yeh R, Ehrinpreis M. Fatal hyperphosphatemia from a phospho-soda

bowel preparation: a case report. J Clin Gastroenterol 2002; 34: 457-8. 34. Nagothu K, Jaszewski R, Moragoda L, Rishi AK, Finkenauer R, Tobi M, Naumoff

JA, Dhar R, Ehrinpreis M, Kucuk O, Majumdar APN. Folic acid mediated attenuation of loss of heterozygosity of DCC tumor suppressor gene in the colonic mucosa of patients with colorectal adenomas. Cancer Detection and Prevention 2003; 27: 297-304.

35. Ehrinpreis M. Debate-Should the National GI fellowship matching program

be restored? Con: the gastroenterology fellowship match: R.I.P. Am J Gastroenterol 2004; 99:7-9.

36. Perez NE, Phillips CR, Webber JD, Guzman CB, Saksouk FA, Ehrinpreis MN. Jejunal obstruction caused by a calcified enterolith. Pract Gastro- enterol 2006; 30:49-53. 37. Perez NE, Siddiqui FA, Mutchnick MG, Dhar R, Tobi M, Ullah N, Saksouk FA, Wheeler DE, Ehrinpreis MN. Ultrasound diagnosis of fatty liver in patients with chronic liver disease; a retrospective observational study. J Clin Gastroenterol 2007;41:624-9. 38. Pawa S, Ehrinpreis M, Mutchnick M, Janisse J, Dhar R, Siddiqui FA. Percutaneous liver biopsy is safe in chronic hepatitis C patients with end stage renal disease. Clin Gastroenterol Hepatol 2007 (in press). 39. Pawa S, Khalifa AJ, Ehrinpreis MN, Schiffer CA, Siddiqui FA. Zinc toxicity from massive and prolonged coin ingestion in an adult. Am J Med Sci 2007 (in press).

11Original Observations in Non-Refereed Journals: 1. Luk GD, Moshier JA, and Ehrinpreis MN: Ornithine decarboxylase: A new

marker for colorectal polyps and cancer? Dept. Med. Bulletin, Wayne State University. 2:4-10,1988. Review Articles: 1. Ehrinpreis MN: Recent Advances in Gastroenterology, IAD Buchier (editor),

Churchill Livingstone, New York, 1980. N Eng J Med 304:367, 1981. 2. Ehrinpreis MN: Nutrition and Diet Therapy in Gastrointestinal Disease. MH Floch

(editor), Plenum Press, New York, 1981. N Eng J Med 306:943, 1982. 3. Ehrinpreis MN: Clinical Nutrition, Taylor KB and Anthony LE, McGraw-Hill, New

York, 1983 and Obesity. MRC Greenwood (editor), Churchill Livingstone, New York, 1983, N Eng J Med 309:1332, 1983.

4. Ehrinpreis MN, Kinzie JL, Jaszewski R, and Peleman RR: Management of the

malignant polyp. Gastroenterology Clin. N. Amer., 17:837-850, 1988. 5. Peleman RR, Kinzie JL, Desai TK, and Ehrinpreis MN: Colonoscopic

polypectomy. Gastroenterology Clin. N. Amer. 17:851-858, 1988. 6. Silverman AL, Desai TK, Dhar R, Ehrinpreis MN, Kinzie JL, and Luk GD: Clinical

features, evaluation, and detection of colorectal cancer. Gastroenterology Clin. N. Amer. 17:713-725, 1988.

7. Ehrinpreis MN: Anorectal Disease in AIDS. TG Allen-Mersh and L Gottesman

(editors) Edward Arnold, London, 1991, N Eng J Med 328:451-2, 1993. 8. Mutchnick MG, Ehrinpreis MN, Kinzie JL, and Peleman RR: Prospectives on the

treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. Antiviral Research 24:245-257, 1994.

9. Jaszewski R, Ehrinpreis MN, Majumdar APN: Aging and cancer of the stomach and colon. Frontiers in Bioscience 4:322-328, 1999. Books and Chapters:

1. Ehrinpreis MN: Nutrition in Hepatic Failure. Nutrition and Metabolism in the

Surgical Patient. JR Kirkpatrick and MS Dahn (Editors), Futura, Mt. Kisco, New York, pp 357-383, 1983.

2. Luk GD, Moshier JA, Ehrinpreis MN: Ornithine Decarboxylase as a Marker for

Colorectal Polyps and Cancer. Basic and Clinical Perspectives of Colorectal Polyps and Cancer. Steele G Jr, Burt RW, Winawer SJ, Karr JP (Eds), Progress in Clinical and Biological Research 1988;279:227-239.

3. Ehrinpreis MN, Alousi MA: Atrophic gastritis. Gastritis, RA Kozol (Editor), CRC Press, Boca Raton, pp 159-182, 1993.

12 4. Ehrinpreis MN: Toxic Megacolon, Diarrhea, Lower Gastrointestinal Hemorrhage (3 chapters). The Saunders Manual of Critical Care, JA Kruse (Editor), W.B.Saunders Company, Orlando, Florida, pp 466-476, 2003. Educational Material 1. Monograph: "Jaundice: A problem-oriented approach" for Year II Wayne State

University Gastrointestinal Pathophysiology Course syllabus. PUBLISHED ABSTRACTS: 1. Ehrinpreis M, M Rojkind, and M-A Giambrone: Dynamics of liver collagen

synthesis in CC14-treated rats. Gastroenterology 73(5):A33, 1977. 2. Rojkind M, M-A Giambrone, and M Ehrinpreis: Proline oxidase activity and the

availability of proline for collagen biosynthesis in livers in CC14- treated rats. Gastroenterology 73(5):A131, 1977.

3. Ehrinpreis M and K Gasser: Relationship between hepatic and plasma free proline

concentrations in CC14-treated rats. Gastroenterology 77(5):A10, 1979. 4. Weinstock JV, DL Boros, MN Ehrinpreis, and JB Gee: Effect of angiotensin I

converting enzyme (ACE) inhibitor on the granulomatous response to schistosoma mansoni eggs in mice. Gastroenterology 78(5):1289, 1980.

5. Ehrinpreis M and K Gasser: Free proline generation and the increased free proline

pool in fibrotic liver of CC14-treated rats. Gastroenterology 79(5):1014, 1980. 6. Ehrinpreis M, K Gasser, and E Urdanivia: Hepatic collagen and free proline

concentrations in rats with experimental diabetes mellitus. Gastroenterology 80(5):1331, 1981.

7. Beisel KW, PS Bhathal, MN Ehrinpreis, IR MacKay, and NR Rose: Genetic control

of murine susceptibility to carbon tetrachloride-induced liver damage. Fed Proc 40(3, pt. 1):765, 1981.

8. Ehrinpreis M, L Lai, and K Beisel: Carbon tetrachloride (CCl4)-induced hepatic

fibrosis in inbred mouse strains. Hepatology 2:700, 1982. 9. Jaszewski R, M Ehrinpreis, and L Lai: Cimetidine and centrizonal necrosis confer

resistance to acetaminophen hepatotoxicity in mice. Hepatology 2:700, 1982. l0. Flore MR, V Wojnar, and MN Ehrinpreis: Impact of skin testing during TPN in a

cancer patient population. JPEN 9:l24, l985. 11. Ahmad I, M Ehrinpreis, A Narula, A Mehdiratta, J Kinzie, and E Luby: Prolonged intestinal transit time in eating disorder patients. Clinical Research 35(2), 1987.

1312. Gupta T and MN Ehrinpreis: Candida-associated diarrhea in hospitalized

patients. Gastroenterology 94(5): 162, 1988. 13. Madhok D, R Peleman, MN Ehrinpreis, C Sugawa, GD Luk, and AL Silverman:

The presence of ascites is associated with infections and fever after sclerotherapy. Gastroenterology 94(l5): 277, 1988.

14. DeVore MS and Ehrinpreis MN: Comparison of dosages of diazepam versus

midazolam in GI endoscopy. Gastrointestinal Endoscopy 34(2)" 171, 1988. 15. Korlipara AP, Ehrinpreis MN, Luk GD, and Peleman RR: Blind cytology brushing

as a method of diagnosis of esophageal candidiasis. Gastrointestinal Endoscopy 34(2): 205, 1988.

16. Jaszewski R, Weinstock JV, Tolia V, Ehrinpreis M, Bodzin J, Peleman, R, and

Korlipara R: Colonic mucosal levels of angiotensin I (AI) and II (AII) distinguish Crohn's colitis from ulcerative colitis. Gastroenterology 96(5): A238, 1989.

17. Gupta T, Maliakkal BJ, Peleman R, Ehrinpreis M, Weaver D, and Luk GD:

Complications of surgical (SG) and percutaneous endoscopic gastrostomy (PEG). Gastroenterology 96(5): A190, 1989.

18. Neelam S, Maliakkal BJ, Ehrinpreis, Luby E, Martin S, Luk GD, and Kinzie J: Total

parenteral nutrition (TPN) in primary anorexia nervosa (AN). Gastroenterology 96(5): A362, 1989.

19. Mehta R, Martin S, Kudla V, Ehrinpreis M, Kinzie J, and Luk GD: Comparison of

the incidence of catheter related sepsis (CPS) in hospital (ITPN) and home-treated patients (HTPN) with total parenteral nutrition. Gastroenterology 96(5): A339, 1989.

20. Maliakkal BJ, Kinzie J, Neelam S, Luby E, Ehrinpreis M, Martin S, and Luk GD:

Admission laboratory values in the assessment of nutritional status in anorexia nervosa. Gastroenterology 96(5): A376, 1989.

21. Lans J, Ehrinpreis M, Poplin E, Baker, Luk GD, and Peleman R: Gastrointestinal

complications of hepatic artery infusion (HAI) pumps. Gastroenterology 96(5): A286, 1989.

22. Desai T, Hinch L, Shah S, Ehrinpreis M, and Kinzie J: Elemental diet/ intralipid

restricted regimen reduces risk of bacteremia in bone marrow transplantation. JPEN 14:21S, 1990.

23. Desai TK, Mehta R, Lan G, Kinzie JL, Luk GD, and Ehrinpreis MN: Intralipid

infusions and septicemia in bone marrow transplant recipients. Gastroenterology 98(5):A409, 1990.

24. Desai TK, Meyerson S, Hinch L, Kinzie J, Ehrinpreis MN, Peleman R, Lum L, et al.: Strict elemental diet/intralipid (IL) restricted parenteral nutrition (PN) may reduce gram negative bacteremia in allogeneic bone marrow transplantation. Gastroenterology 100(5):A519, 1991.

1425. Maliakkal BJ, Katta S, Cejka J, Ehrinpreis MN, Kinzie JL, and Desai TK: Severe

acute taurine deficiency after cancer chemotherapy. Gastroenterology 100(5): A534, 1991.

26. Reddy J, Bakst C, Cronin S, Kinzie J, Ehrinpreis MN, Desai TK, et al.: Lipid

restriction may reduce severity of parenteral nutrition (PN) related liver disease in bone marrow transplantation (BMT). Gastroenterology 100(5):A544, 1991.

27. Barbish AW and Ehrinpreis MN: Successful sclerotherapy of bleeding duodenal

varices. Am J Gastroenterol 86:1366, 1991. 28. Tobi M, Kaila V, Goo R, Kinzie J, Ehrinpreis M, Maliakkal B, Yang S, Chintalapani

S, Cats A, and Luk G: An adenoma-associated antigen as a proneoplastic marker in familial polyposis coli versus sporadic colonic neoplasia. Gastroenterology 102(4): A403, 1992.

29. Polidori G, Holtz T, Kinzie J, Kellogg C, Ehrinpreis M, and Peleman R: A cluster of

rota-virus associated diarrhea identified in bone-marrow- transplant recipients. Gastroenterology 102(4):A680, 1992.

30. Meyerson S, Peleman R, and Ehrinpreis M: Prevalance of helicobacter pylori (HP)

in HIV infected patients compared to age-matched controls using urease testing. Am J Gastroenterol 87(9):1272, 1992.

31. Desai TK, Reddy J, Kinzie JL, Ehrinpreis MN. Taurine supplementation and

cholestasis during bone marrow transplantation. Gastroenterology 104:A616, 1993.

32. Meyerson S, Holtz T, Ehrinpreis MN, and Dhar R. Small bowel obstruction during

pregnancy. Am J Gastroenterol 88(9):1593, 1993. 33. Shah G, Augustine S, Cummings G, Ehrinpreis M. Pre-eclampsia, liver function

abnormalities and cocaine use during pregnancy. Gastroenterology 106:A980, 1994.

34. Reddy R, Blatt LM, Conrad A, Tong MJ, Lubina J, Smith C, Ehrinpreis MN, Bala K,

Willems BE, White H, Black M, Donovan J, Bailey RJ, and the Consensus Interferon Study Group. Genotype distribution in 815 chronic HCV infected patients in North America. Gastroenterology 110:A1303, 1996.

35. Hollinger FB, Blatt LM, Tong MJ, Conrad A, Balart L, Pockros P, Bonkovsky HL,

Ehrinpreis MN, Lubina J, and the Consensus Interferon Study Group. Differential response to treatment with consensus interferon and IFN-α 2b in chronic HCV patients infected with genotype 1b. Gastroenterology 110:A1213, 1996.

36. Craig JR, Bain VG, Black M, Cruickshank S, Ehrinpreis M, Foust R, Hofling D, Lee

W, Sarosi I, Smith CI, Van Leeuwen DJ, and the Consensus Interferon Study Group. Liver histology improvement is associated with ALT and HCV RNA response following treatment with consensus interferon (CIFN). Gastroenterology 110:A1175, 1996.

1537. Naylor PH, Nathani M, Peleman R, Ehrinpreis MN, Mutchnick MG. Comparison

of two HBV-DNA hybridization assays of sera from patients completing a clinical trial of thymosin α1 (Tα1) in chronic hepatitis B (CHB). Gastroenterology 110:A1276, 1996.

38. Craig JR, Bain VG, Ehrinpreis M, Foust R, Lee W, Smith CI, van Leeuwen DJ, and

the Consensus Interferon Study Group. Liver histology improves in both cirrhotic and non-cirrhotic patients with chronic HCV infection following consensus interferon (CIFN) therapy. Gastroenterology 112:A1248, 1997.

39. Nathani M, Ehrinpreis M, Naylor P, Lybik M, Peleman R, Kinzie J, Mutchnick

M. The demographic analysis of chronic hepatitis C patients within a metropolitan community practice. Gastroenterology 114:L0460, 1998.

40. Siddiqui F, Nathani M, Kumar A, Mutchnick M, Peleman R, Kinzie J, Ehrinpreis M. Prevalence of hepatitis A and hepatitis B immunity in patients with PCR- confirmed hepatitis C. Gastroenterology 114:L0597 1998. 41. Shahzad S, Bentley G, Nathani MG, Naylor PH, Ehrinpreis MN, Peleman RR, Kinzie JL, Mutchnick MG. Viral load, age, race, gender and serum transaminase levels predict histological grade and stage in hepatitis C virus (HCV) infection. Hepatology 28; 201A, 1998. 42. Ehrinpreis MN, Nathani MG, Naylor PH, Peleman RR, Kinzie JL, Lybik M, Mutchnick MG. Race, hepatitis C genotype and ALT>AST predict the probability of response to interferon in an urban clinic population of patients with chronic hepatitis C. Hepatology 28; 204A, 1998. 43. Everson GT, Jensen DM, Craig JR, vanLeewen DJ, Bain VG, Ehrinpreis MN, Albert D, Joh T, Witt K, et al. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, bridging fibrotocs, or nonfibrotics. Hepatology 28; 209A, 1998. 44. Peleman RR, Naylor PH, Ehrinpreis MN, Nathani MG, Kinzie JL, Lybik M, Siddiqui F, Mutchnick MG. Serum HCV RNA levels as determinants for dose escalation of interferon: results from studies in an urban clinic population. Hepatology 28; 370A, 1998. 45. Nathani MG, Naylor PH, Ehrinpreis MN, Kinzie JL, Lybik M, Peleman RR, Mutchnick MG. Three negative PCR for HCV RNA at intervals of one month are not adequate to predict a sustained response to interferon. Hepatology 28; 702A, 1998. 46. Siddiqui F, Naylor PH, Ehrinpreis MN, Peleman RR, Kinzie JL, Mutchnick MG: Induction interferon treatment of African-Americans with hepatitis C results in an enhanced response comparable to Caucasians given standard interferon therapy. Gastroenterology 116: A820, 1999.

16 47. Ullah N, Siddiqui FA, Naylor PH, Kinzie JL, Ehrinpreis MN, Peleman RR, Mutchnick MG. Presence of hepatitis B virus core antibodies (Anti-HBC) in chronic hepatitis C patients is predictive of a decreased end of treatment response (ETR) to interferon. Hepatology 30:195A, 1999. 48. Kinzie JL, Naylor PH, Ehrinpreis MN, Khan N, Siddiqui FA, Peleman

RR, Mutchnick, MG. Reluctance of urban clinic patients to undergo treatment with interferon-alpha. Hepatology 30: 266A, 1999.

49. Naylor PH, Brown KA, Gordon SC, Moonka D., Silverman AL, Kinzie

JL, Ehrinpreis MN, Peleman RR, Mutchnick MG. Response to retreatment with interferon/ribavirin in Caucasian and African American relapsers and nonresponders. Hepatology 30: 373A, 1999.

50. Naylor PH, Podzorski R, Dhar R, Ehrinpreis MN, Kinzie JL, Siddiqui F,

Mutchnick MG. Two laboratory methods for measuring serum HCV RNA in patients with hepatitis C are equal with respect to determining and predicting end of treatment response to interferon therapy. Antiviral Therapy 4(supplement 4) A87, 1999.

51. Naylor PH, Kinzie JL, Ehrinpreis MN, Siddiqui F, Dhar R, Turner JR, Mutchnick MG. Retreatment of interferon failures with combination therapy: log drop after 12 weeks of monotherapy predicts ETR to combination therapy. Antiviral Therapy 5: C191, 2000.

52. Khalifa-Alsaleh A, Naylor PH, Kinzie JL, Ehrinpreis MN, Siddiqui F, Dhar R, Turner

JR, and Mutchnick MG.: End of treatment response (ETR) to Intron A monotherapy in chronic hepatitis C is similar in patients with normal and elevated ALT. Antiviral Therapy 2000; 5: C190.

53. Weidler N, Naylor PH Patel CM, Chilukuri S, Mendu S, Janisse JJ, Dhar R,

Ehrinpreis MN, Kinzie JL, Siddiqui F, Turner JR, Mutchnick MG. Demographical and biochemical influences on quality of life scores in urban patients with Hepatitis C. Gastroenterology 2000; 118(Supp 2): A995

54. Kulkarni PM, Kinzie JL, Ehrinpreis MN. Argon plasma coagulator treatment in the

management of hematochezia secondary to chronic radiation proctopathy. Am J Gastroenterol 2000; 95:2539.

55. Ullah N, Yeh R, Ehrinpreis MN. Fatal hyperphosphatemia after oral phospho-soda

preparation for colonoscopy: a case report and review of the literature. Am J Gastroenterol 2000; 95: 2613.

56. Yeh R, Ullah N, Ehrinpreis MN. Role of lamivudine in the treatment of acute

hepatitis B infection associated with polyarteritis nodosa. Am J Gastroenterol 2000; 95: 2615.

17 57. Naylor PH, Meija L, Kinzie JL, Ehrinpreis MN, Dhar R, Siddiqui F, Turner JR,

Mutchnick MG. Tumor necrosis factor-a and chronic hepatitis C: lower serum levels in African Americans as compared to Caucasians. Hepatology 2000; 32(pt. 2): 263A.

58. Alawad G, Naylor PH, Hemacha A, Jamma K, Weidler N, Kinzie JL,

Ehrinpreis MN, Dhar R, Mutchnick MG.: Differences in side effect profiles and response to combination ribavirin and interferon a2b (IFN) therapy between Caucasians and African Americans with chronic hepatitis C. Hepatology 2000; 32(pt. 2): 368A.

59. Siddiqui FS, Naylor PH, Ehrinpreis MN, Dhar R, Turner J, Murthy R, Kulkarni P,

Boag J, Mutchnick MG: Biochemical, histological and clinical comparisons between African-American and Caucasian patients with chronic hepatitis C in an urban clinic population. Gastroenterology 2001; 120(Suppl 1): A365.

60. Khalifa A, Siddiqui F, Ehrinpreis M. A case of zinc toxicity due to massive coin

ingestion. Am J Gastroenterol 2001;96(Suppl):S213. 61. Ullah N,Lucas D, Yeh R, Akhras J, Ehrinpreis M, Kulkarni P. Overt-obscure GI

bleeding from an unusual small bowel lesion in an HIV patient previously treated for Kaposi’s sarcoma. Am J Gastroenterol 2001;96(Suppl):S353.

62. Kulkarni PM, Mutchnick MG, Ehrinpreis MN. Sero-prevalence of hepatitis B and C

in a large university-based sickle-cell practice. Hepatology 2001;34(4pt.2):564A. 63. Shahin G, Naylor PH, Mutchnick MG, Siddiqui FA, Turner JR, Dhar R, Murthy R,

Ehrinpreis MN. Influence of hepatitis C infection on gallstone prevalence in urban patients. Hepatology 2001;34(4pt.2):565A.

64. Kulkarni PM, Mutchnick MG, Migdal SD, Ehrinpreis MN. Hepatitis B and C in urban

hemodialysis centers: a Detroit experience. Hepatology 2001;34(4pt.2):565A. 65. Siddiqui FA, Ehrinpreis MN, Naylor PH, Dhar R, Murthy R, Boag J, Mutchnick MG.

Response to combination treatment in African-American patients with chronic hepatitis C is significantly lower compared to Caucasians. Hepatology 2001;34(4pt.2):581A.

66. Siddiqui FA, Naylor P, Ehrinpreis M, Dhar R, Murthy R, Mutchnick M. African-

Americans with chronic hepatitis C respond poorly to interferon/ribavirin combination treatment even when induction regimens are used. Gastroenterology 2002;123(1suppl.1):77A (T1402).

67. Al-Subee O, Ehrinpreis M, Tyburski J. Pneumatosis coli associated with

cryptosporidiosis of the GI tract in AIDS patients. Am J Gastroenterol 2002;97(Suppl):S169.

68. Siddiqui F, Ehrinpreis M, Singh A, Dhar R, Murthy R, Mutchnick M. Prevalence of

chronic hepatitis C infection in patients with hepatocellular carcinoma in an inner city population. Hepatology 2002;36(4pt.2):703A.

18 69. Zalewska I, Siddiqui F, Ehrinpreis M, Dhar R, Murthy R, Ranieri L, Janisse J,

Mutchnick M. African Americans failing treatment with interferon monotherapy for chronic hepatitis C are less likely to achieve sustained response to subsequent treatments compared to Caucasians. Gastroenterology 2003;124(4suppl.1):A-781(T1278).

70. Pawa S, Ehrinpreis MN, Mutchnick MG, Dhar R, Siddiqui F. Percutaneous

liver biopsy in chronic hepatitis C patients with end stage liver disease. Gastroenterology 2004;126(4suppl.2):A719(M1220).

71. Duttala S, Al-Subee O, Ehrinpreis M. Retrospective analysis of patients

diagnosed with colorectal cancer above age of 75 by colonoscopy. Gastrointest Endosc 2004;59:AB280(W1656).

72. Pawa S, Mutchnick M, Ehrinpreis M, Dhar R, Greer J, Siddiqui FA. Patients

with chronic hepatitis C and chronic renal insuffieiency or end stage renal disease respond poorly to interferon monotherapy. Hepatology 2004;36(4suppl.1):332-333A.

73. Perez N, Ullah N, Tobi M, Wheeler D, Saksouk F, Ehrinpreis M. Fat or fiction:

ultrasound diagnosis of fatty liver in patients with chronic liver disease. Am J Gastroenterol 2005;100(9Suppl):S108.

74. Perez N, Phillips C, Webber J, Ehrinpreis M. Jejunal obstruction caused by

an enterolith. Am J Gastroenterol 2005;100(9Suppl):S204. 75. Khan A, Mutchnick M, Ehrinpreis M, Dhar R, Siddiqui F. African-Americans

with genotype-1 with chronic hepatitis C respond poorly to pegylated-interferon and ribavirin combination treatment as compared to Caucasians. Am J Gastroenterol 2005;100(9Suppl):S126.

76. Hammad H, Diez A, Perez N. Wiese W, Ehrinpreis, M. Hepatitis B flare after

cessation of HAART. Am J Gastroenterol 2006;101(9 Suppl):S282. 77. Pawa S, Greene M, Ehrinpreis, M. Ischemic colitis associated with epsilon-

aminocaproic acid therapy. Am J Gastroenterol 2006;101(9 Suppl):S285. 78. Maryala S, Perez N, Chandravanka C, Ehrinpreis M. Esophageal

actinomycosis. Am J Gastroenterol 2006;101(9 Suppl):S286. 79. Reyes P, Pawa S, Ehrinpreis M. Intestinal Ganglioneuromatosis Polyposis:

A rare cause of abdominal pain. Am J Gastroenterol 2006; 101(9 Suppl):S378.

80. Hammad H, Perez N, Dahche T, Ehrinpreis M. GVHD of the GI tract after BMT:

are both upper and lower endoscopies necessary to make the diagnosis? Gastroenterology 2007;132(4Suppl2):A193(S1197).

1981. Hammad H, Razumilava N, Perez N, Ehrinpreis M. Gastrointestinal

bleeding in biopsy-proven graft-versus-host disease of the GI tract: risk factors and effect on mortality. Am J Gastroenterol 2007;102(9Suppl):S453.

82. Seren S, Bayraktar U, Ehrinpreis M. Characteristics of patients with reflux

esophagitis, non-erosive reflux disease and functional heartburn. Am J Gastroenterol 2007;102(9Suppl):S130.

83. Seren S, Bayraktar U, Ehrinpreis M. Esophageal pH monitoring with Bravo™

capsule in patients with suspected gastroesophageal reflux disease. Am J Gastroenterol 2007;102(9Suppl):S130.

PRESENTATIONS: Invited Internationally: 1. Invited Speaker: Marmara University Hospital, Istanbul, Turkey, April 29, 1994 -

May11, 1994, Lectures and Endoscopic Procedures. 2. Ehrinpreis MN: Inflammatory bowel disease. Plenary presentation and

symposium at 24th International Congress of Internal Medicine, Lima, Peru. November 4-5, 1998.

Invited Nationally: 1. Flore MR, V Wojnar, and MN Ehrinpreis: Impact of skin testing done during TPN in

a cancer patient population. Presented at ASPEN 9th Clinical Conference, Miami Beach, January 22, 1985.

2. Facca B, M Ehrinpreis, and L Franchina: Serum transferrin and nitrogen balance.

Presented at Nutrition Practice Poster Session, ASPEN 12th Clinical Conference, Las Vegas, January 19, 1988.

3. Gupta T and MN Ehrinpreis: Candida-associated diarrhea in hospitalized patients.

Presented at the AGA National Meeting, New Orleans, May 18, 1988. 4. "Cytotec Study Investigators Seminar, Searle Corporation." Scottsdale, Arizona,

March 12, 1988. 5. Jaszewski R, Weinstock JV, Tolia V, Ehrinpreis M, Bodzin J, Peleman R, and

Korlipara P: Colonic mucosal levels of angiotensin I and II distinguish Crohn's colitis from ulcerative colitis. Presented at the AGA national meeting, Washington DC, May 1989.

6. Desai T, Hinch L, Shah S, Ehrinpreis M, and Kinzie J: Elemental diet/ intralipid

restricted regimen reduces risk of bacteremia in bone marrow transplantation. Presented at ASPEN 14th Clinical Conference, San Antonio, Jan 29, 1990.

7. Castillo M and Ehrinpreis MN: Diarrhea in hospitalized patients: The roles of stool

cultures, antibiotics, candida. Presented at the Midwest Gut Club, Detroit, MI, March 3, 1990.

20 8. Spitzer AR and Ehrinpreis M: Electrophysiologic distinction of Serotonin -

responsive and unresponsive myoclonus. Presented at the First International Congress of Movement Disorders, Washington, D.C., April 1990.

9. Desai TK, Mehta R, Lan G, Kinzie JL, Luk GD, and Ehrinpreis MN: Intralipid

infusions and septicemia in bone marrow transplant recipients. Presented at the AGA national meeting, San Antonio, May 16, 1990.

10. Ehrinpreis MN: "Update on Nutrition in Hospitalized Patients." Presented at

Medical Grand Rounds, Texas Tech. University, El Paso, Texas, April 6, 1990. 11. Desai TK, Meyerson S, Hinch R, Kinzie JL, Peleman R, Lum L, Ehrinpreis MN, and

the Bone Marrow transplant team: Strict elemental diet/intralipid restricted parenteral nutrition may reduce gram negative bacteremia in allogenic bone marrow transplantation. Presented at AGA national meeting, New Orleans, May 1991.

12. Tobi M, Kaila V, Goo R, Kinzie J, Ehrinpreis M, Maliakkal B, Yang S, Chintalapani

S, Cats A, and Luk G: An adenoma-associated antigen as a proneoplastic marker in familial polyposis coli versus sporadic neoplasia. Presented at AGA National Meeting, San Francisco, May 13, 1992.

13. Meyerson S, Peleman R, and Ehrinpreis M: Prevalence of Helicobacter pylori (HP)

in HIV infected patients compared to age-matched controls using urease testing. Presented at ACG National Meeting, Miami Beach, October 26, 1992.

14. Desai TK, Reddy J, Kinzie JL, and Ehrinpreis MN: Taurine supplementation and

cholestasis during bone marrow transplantation. Presented at the AGA National Meeting, Boston, May 18, 1993.

15. Meyerson S, Holtz T, Ehrinpreis MN, and Dhar R: Small bowel obstruction during

pregnancy. Presented at the ACG National Meeting, New York, October 4, 1993. 16. Reddy R, Blatt LM, Conrad A, Tong MJ, Lubina J, Smith C, Ehrinpreis MN, Bala K,

Willems BE, White H, Black M, Donovan J, Bailey RJ, and the Consensus Interferon Study Group. Genotype distribution in 815 chronic HCV infected patients in North America. Presented at AGA National Meeting, San Francisco, May, 1996.

17. Hollinger FB, Blatt LM, Tong MJ, Conrad A, Balart L, Pockros P, Bonkovsky HL,

Ehrinpreis MN, Lubina J, and the Consensus Interferon Study Group. Differential response to treatment with consensus interferon and IFN-" 2b in chronic HCV patients infected with genotype 1b. Presented at AGA National Meeting, San Francisco, May, 1996.

18. Lybik M, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Kinzie JL,

Mutchnick MG. The demographics and analysis of the routes of acquisition of hepatitis C in a community practice. Presented at the 2nd International Conference on Therapies for Viral Hepatitis, Big Island, Hawaii, December 18, 1997.

2119. Nathani MG, Naylor PH, Lybik M, Peleman RR, Ehrinpreis MN, Kinzie JL,

Mutchnick MG. Distribution of HCV RNA and genotype in a community practice setting. Presented at the 2nd International Conference on Therapies for Viral Hepatitis, Big Island, Hawaii, December 18, 1997.

20. Siddiqui F, Nathani M, Kumar A, Mutchnick M, Peleman R, Kinzie J, Ehrinpreis M.

Prevalence of hepatitis A and hepatitis B immunity in patients with PCR-confirmed hepatitis C. Presented at the Midwest Gut Club Meeting, Cleveland, Ohio, March 1998.

21. Siddiqui F, Nathani M, Kumar A, Mutchnick M, Peleman R, Kinzie J, Ehrinpreis M.

Prevalence of Hepatitis A and Hepatitis B Immunity In Patients With PCR-Confirmed Hepatitis C. Presented at the Digestive Disease Week, New Orleans, LA. May 18, 1998.

22. Shahzad S, Bentley G, Nathani MG, Naylor PH, Ehrinpreis MN, Peleman RR, Kinzie JL, Mutchnick MG. Viral load, age, race, gender and serum transaminase levels predict histological grade and stage in hepatitis C C virus (HCV) infection. Presented at the International Association for the Study of the Liver, Bienniel Scientific Meeting, Chicago, IL. November 4, 1998.

23. Ehrinpreis MN, Nathani MG, Naylor PH, Peleman RR, Kinzie JL, Lybik M,

Mutchnick MG. Race, hepatitis C genotype and ALT>AST predict the probability of response to interferon in an urban clinic population of patients with chronic hepatitis C. Presented at the International Association for the Study of the Liver, Bienniel Scientific Meeting, Chicago, IL. November 4, 1998.

24. Everson GT, Jensen DM, Craig JR, vanLeewen DJ, Bain VG, Ehrinpreis MN, Albert D, Joh T, Witt K, et al. Efficacy of interferon treatment for patients with

chronic hepatitis C: Comparison of response in cirrhotics, bridging fibrotocs, or nonfibrotics. Presented at the International Association for the Study of the Liver, Bienniel Scientific Meeting, Chicago, IL. November 4, 1998.

25. Peleman RR, Naylor PH, Ehrinpreis MN, Nathani MG, Kinzie JL, Lybik M, Siddiqui

F, Mutchnick MG. Serum HCV RNA levels as determinants for dose escalation of interferon: results from studies in an urban clinic population. Presented at the American Association for the Study of Liver Diseases, Chicago, IL. November 4, 1998

26. Anania F, Ehrinpreis MN: "Management of HCV infected patients with

compensated cirrhosis." Workshop and presentation at Amgen Clinical Development Investigators Meeting. Maui, Hawaii. December 4, 1998.

27. Siddiqui F, Naylor PH, Ehrinpreis MN, Peleman RR, Kinzie JL, Mutchnick MG:

Induction interferon treatment of African-Americans with hepatitis C results in an enhanced response comparable to Caucasians given standard Interferon therapy. Presented at Digestive Disease Week, Orlando, FL, May 17, 1999.

22 28. Ullah N, Siddiqui FA, Naylor PH. Kinzie JL, Ehrinpreis M, Peleman RR,

Mutchnick MG,: Presence of hepatitis B virus core antibodies (Anti-HBC) in chronic hepatitis C patients is predictive of a decreased end of treatment response (ETR) to interferon. Presented at AASLD, Dallas, TX. November 6, 1999.

29. Kinzie JL, Naylor PH, Ehrinpreis MN, Khan N, Siddiqui FA, Peleman

R R, Mutchnick MG. Reluctance of urban clinic patients to undergo treatment with interferon-alpha. Presented at AASLD, Dallas, TX. November 6, 1999.

30. Naylor PH, Brown KA, Gordon SC, Moonka D, Silverman AL, Kinzie JL, Ehrinpreis MN, Peleman RR, Mutchnick MG: Response to retreatment with interferon/ribavirin in Caucasian and African American relapsers and nonresponders. Presented at AASLD, Dallas, TX. November 8,1999.

31. Naylor PH, Kinzie JL, Ehrinpreis MN, Siddiqui F, Dhar R, Turner JR, Mutchnick

MG. Retreatment of interferon failures with combination therapy: log drop after 12 weeks of monotherapy predicts ETR to combination therapy. Presented at Tenth International Symposium on Viral Hepatitis and Lime Disease, April 9-13, 2000, Atlanta, GA

32. Khalifa-Alsaleh A, Naylor PH, Kinzie JL, Ehrinpreis MN, Siddiqui F, Dhar R, Turner JR, and Mutchnick MG.: End of treatment response (ETR) to Intron A monotherapy in chronic hepatitis C is similar in patients with normal and elevated ALT. Presented at 10th Int’l Symposium on Viral Hepatitis and Liver Disease, Atlanta, GA, April 10, 2000

33. Weidler N, Naylor PH Patel CM, Chilukuri S, Mendu S, Janisse JJ, Dhar R,

Ehrinpreis MN, Kinzie JL, Siddiqui F, Turner JR, Mutchnick MG. Demographical and biochemical influences on quality of life scores in urban patients with hepatitis C. Presented at DDW, San Diego, May 22, 2000.

34. Kulkarni PM, Kinzie JL, Ehrinpreis MN. Argon plasma coagulator treatment in the

management of hematochezia secondary to chronic radiation proctopathy. Presented at ACG Annual Scientific Meeting, New York, October 6-18, 2000.

35. Ullah N, Yeh R, Ehrinpreis MN. Fatal hyperphosphatemia after oral phospho-

soda preparation for colonoscopy: a case report and review of the literature. Presented at ACG Annual Scientific Meeting, New York, October 16-18, 2000.

36. Yeh R, Ullah N, Ehrinpreis MN. Role of lamivudine in the treatment of acute

hepatitis B infection associated with polyarteritis nodosa. Presented at ACG Annual Scientific Meeting, New York, October 16-18, 2000

37. Naylor PH, Meija L, Kinzie JL, Ehrinpreis MN, Dhar R, Siddiqui F, Turner JR, Mutchnick MG. Tumor necrosis factor-a and chronic hepatitis C: low serum levels in African Americans as compared to Caucasians. Presented at AASLD, Dallas, 10/29/00.

23 38. Alawad G, Naylor PH, Hemacha A, Jamma K, Weidler N, Kinzie JL, Ehrinpreis MN, Dhar R, Mutchnick MG.: Differences in side effect profiles and response to combination ribavirin and interferon a2b (IFN) therapy between Caucasians and African Americans with chronic hepatitis C. Presented at AASLD, Dallas, 10/30/00. 39. Siddiqui FA, Naylor PH, Ehrinpreis MN, Dhar R, Turner J, Murthy R, Kulkarni P, Boag J, Mutchnick MG: Biochemical, histological and clinical comparisons between African-American and Caucasian patients with chronic hepatitis C in an urban clinic population. Presented at DDW, Atlanta, 5/21/2001. 40. Khalifa A, Siddiqui F, Ehrinpreis M. A case of zinc toxicity due to massive

coin ingestion. Presented at the ACG Annual Scientific Meeting, Las Vegas, 10/23/2001.

41. Siddiqui FA, Naylor P, Ehrinpreis M, Dhar R, Murthy R, Mutchnick M. African-Americans with chronic hepatitis C respond poorly to interferon/ribavirin

combination treatment even when induction regimens are used. Presented at DDW, San Francisco, 5/21/2002.

42. Ehrinpreis MN. Gastrointestinal involvement in scleroderma. Presented at

Scleroderma Foundation National Conference, Las Vegas, 6/30/2002. 43. Al-Subee O, Ehrinpreis M, Tyburski J. Pneumatosis coli associated with

cryptosporidiosis of the GI tract in AIDS patients. Presented at the ACG Annual Scientific Meeting, Seattle, 10/20/02.

44. Zalewska I, Siddiqui F, Ehrinpreis M, Dhar R, Murthy R, Ranieri L, Janisse J,

Mutchnick M. African Americans failing treatment with interferon monotherapy for chronic hepatitis C are less likely to achieve sustained response to subsequent treatments compared to Caucasians. Presented at DDW, Orlando, 5/20/03.

45. Pawa S, Ehrinpreis MN, Mutchnick MG, Dhar R, Siddiqui F. Percutaneous

liver biopsy in chronic hepatitis C patients with end stage liver disease. Presented at DDW, New Orleans, 5/17/04.

46. Duttala S, Al-Subee O, Ehrinpreis M. Retrospective analysis of patients

diagnosed with colorectal cancer above age of 75 by colonoscopy. Presented at DDW, New Orleans, 5/19/04.

47. Pawa S, Mutchnick M, Ehrinpreis M, Dhar R, Greer J, Siddiqui FA. Patients

with chronic hepatitis C and chronic renal insufficiency or end stage renal disease respond poorly to interferon monotherapy. Presented at AASLD, Boston, 10/30/04.

48. Perez N, Ullah N, Tobi M, Wheeler D, Saksouk F, Ehrinpreis M. Fat or fiction:

ultrasound diagnosis of fatty liver in patients with chronic liver disease. Presented at ACG Annual Meeting, Honolulu, 11/2/05.

2449. Perez N, Phillips C, Webber J, Ehrinpreis M. Jejunal obstruction caused by

an enterolith. Presented at ACG Annual Meeting, Honolulu, 10/31/05. 50. Khan A, Mutchnick M, Ehrinpreis M, Dhar R, Siddiqui F. African-Americans

with Genotype-1 with Chronic Hepatitis C Respond Poorly to Pegylated-Interferon and Ribavirin Combination Treatment as Compared to Caucasians. Presented at ACG Annual Meeting, Honolulu, 10/30/05.

51. Hammad H, Diez A, Perez N. Wiese W, Ehrinpreis, M. Hepatitis B flare after

cessation of HAART. Presented at ACG Annual Meeting, Las Vegas, 10/22/06.

52. Pawa S, Greene M, Ehrinpreis, M. Ischemic colitis associated with epsilon-

aminocaproic acid therapy. Presented at ACG Annual Meeting, Las Vegas, 10/22/06.

53. Maryala S, Perez N, Chandravanka C, Ehrinpreis M. Esophageal

actinomycosis. Presented at ACG Annual Meeting, Las Vegas, 10/22/06. 54. Reyes P, Pawa S, Ehrinpreis M. Intestinal ganglioneuromatosis.

polyposis: a rare cause of abdominal pain. Presented at ACG Annual Meeting, Las Vegas, 10/22/06.

55. Pawa S, Ehrinpreis M, Mutchnick M, Dhar R, Janisse J, Siddiqui F. African

American and Caucasian patients with chronic hepatitis C genotype 2 or 3 respond similarly to interferon-based therapies. Presented at EASL Annual Meeting, Barcelona, 4/2007.

56. Hammad H, Perez N, Dahche T, Ehrinpreis M. GVHD of the GI tract after BMT: are both upper and lower endoscopies necessary to make the diagnosis? Presented at DDW, Washington, DC, 5/2007. 57. Hammad H, Razumilava N, Perez N, Ehrinpreis M. Gastrointestinal bleeding in biopsy-proven graft-versus-host disease of the GI tract: risk factors and effect on mortality. Presented at ACG Annual Meeting, Philadelphia, 10/2007. Invited Locally (Selected): 1. Ehrinpreis, MN: "Nutritional Management of Hepatic Failure Patients." Presented

at Fourth Annual Parenteral and Enteral Nutrition Seminar, Michigan Inn, Southfield, September 24, 1983.

2. Ehrinpreis, MN: "Motor Disorders of the Esophagus." Presented at Michigan State

Medical Society Scientific Meeting, Hyatt Regency, Dearborn, November 16, 1983. 3. Ehrinpreis, MN: "Options in Nutritional Support." Presented at Fifth Annual

Parenteral and Enteral Nutrition Seminar, Westin Hotel, Detroit, September 15, 1984.

25 4. Ehrinpreis MN: "Update on Viral Hepatitis." Presented at Wayne State University

Continuing Medical Education "Update in Gastroenterology" seminar at Hyatt Regency, Dearborn, February 26, 1986.

5. Ahmad I, MN Ehrinpreis, A Narula, A Mehdiratta, J Kinzie, and E. Luby:

"Prolonged Small Intestinal Transit Time in Eating Disorder Patients." Presented at ACP Regional Meeting, Traverse City, September 18, 1987.

6. Parikh N and MN Ehrinpreis: "Esophageal Ulceration Due to Slow-released KCl in

a Patient With a Giant Left Atrium." Presented at ACP Regional Meeting, Traverse City, September 17, 1987.

7. Sofian-Conlan EJ, RR Peleman, K Surakomol, and MN Ehrinpreis: "Duodenal Bulb

Mucosal Bridge." Presented at ACP Regional Meeting, Traverse City, September 17, 1987.

8. Ehrinpreis, MN: "Medical Therapy of Inflammatory Bowel Disease". Presented at

Michigan State Med. Society Scientific Meeting, Hyatt Regency, Dearborn, November 11, 1987.

9. Ehrinpreis, MN: "Treatment of Peptic Ulcer Disease." Presented at Medical Grand

Rounds, Holy Cross Hospital, November 17, 1987. 10. Ehrinpreis MN: "When Should We Use GI Endoscopy?" Presented at Michigan State Med. Society Scientific Meeting, Hyatt Regency, Dearborn, MI, November

10, 1988. 11. Ehrinpreis MN: "Esophageal Disorders." Presented at Otolaryngology Grand

Rounds, Wayne State University, January 9, 1988. 12. Ehrinpreis MN: "Peptic Ulcer Disease." Presented at Medical Grand Rounds, St.

Joseph Hospital, Pontiac, February 10, 1988. 13. Ehrinpreis MN: "Nutritional Assessment." Presented at Medical Grand Rounds,

Harper Hospital, February 24, 1988. 14. Ehrinpreis MN: "Diarrhea in the ICU." Presented at Critical Care Symposium,

Wayne State University, March 2, 1988. 15. Ehrinpreis MN: "Management of the Malignant Polyp." Presented at Michigan

Society of Gastrointestinal Assistants, Detroit, October 8, 1988. 16. Ehrinpreis MN: "Jaundice." Presented at Medical Grand Rounds, Holy Cross

Hospital, October 26, 1988. 17. Parikh N, MN Ehrinpreis, C Conteas, and K Bergsman: "Upper Gastrointestinal

Hemorrhage from Metastatic Ovarian Carcinoma." Presented at ACP Regional Meeting Traverse City, September 22, 1989.

26

18. Ehrinpreis MN: "Peptic Ulcer Disease Management Update." Presented at

Michigan State Medical Society Scientific Meeting, Hyatt Regency, Dearborn, Michigan

19. Ehrinpreis MN: "Approach to Nutritional Support in Hospitalized Patients."

Presented at Family Medicine Grand Rounds, Holy Cross Hospital, February 8, 1989.

20. Ehrinpreis MN: "Hepatic Ischemia." Presented at Medical Grand Rounds,

Harper Hospital, July 12, 1989. 21. Ehrinpreis MN. "ABC (DE)'s of Viral Hepatitis." Presented at Michigan State

Medical Society Scientific Meeting, Hyatt Regency, Dearborn, MI, November 8, 1990.

22. Ehrinpreis MN: "Peptic Ulcer Disease." Presented at Sanilac County Medical

Society, Marlette, MI, January 9, 1990. 23. Ehrinpreis MN: "A Patient With Cholestasis." Presented at CPC, Harper Hospital,

October 3, 1990. 24. Ehrinpreis MN: "Pathophysiology and treatment of Peptic Ulcer Disease" and

"NSAID-Induced Gastropathy." Presented at Bon Secour Hospital, Visiting Professor, Grosse Pointe, MI, September 13, 1990.

25. Ehrinpreis MN: "Hepatobiliary Abnormalities and TPN." Presented at Michigan

Society for Parenteral and Enteral Nutrition Annual Meeting, Traverse City, MI, September 21, 1991.

26. Shafiuddin M, Reddy J, and Ehrinpreis MN: "Salmonella Mycotic Aneurysm of the

Common Iliac Artery Masquerading as a Pelvic Abscess." Presented at ACP Regional Meeting, Traverse City, September 1991.

27. Barbish AW and Ehrinpreis MN: "Successful Sclerotherapy of Bleeding Duodenal

Varices." Presented at ACP Regional Meeting, Traverse City, September 1991. 28. Ehrinpreis MN: Candida-induced, antibiotic-associated diarrhea". Presented at GI

Grand Rounds. Beaumont Hospital, Royal Oak, MI, April 2, 1991. 29. Meyerson S, Polidori G, Yang S, Peleman R, Ehrinpreis M, Goo R, and Kinzie J:

"Our Initial Experience With Endoscopic Esophageal Varix Ligation." Presented at ACP Regional Meeting. Traverse City, October 3, 1992.

30. Ehrinpreis MN: "Chronic Gastritis." Presented at Medical Grand Rounds, Grace

Hospital, Detroit, MI, April 2, 1992. 31. Ehrinpreis MN: "Hepatobiliary Abnormalities and TPN." Presented at American

Society for Parenteral and Enteral Nutrition regional course. Ritz Carlton Hotel, Dearborn, MI, May 28, 1992.

27 32. Ehrinpreis MN: "Pathogenesis of Hepatic Inflammation." Presented at Wayne

State University Symposium on Chronic Viral Hepatitis, Mackinac Island, MI, September 11, 1992.

33. Ehrinpreis MN: "Helicobacter pylori, Infection." Presented at Medical Ground

Rounds, Harper Hospital, Detroit, MI, November 10, 1993. 34. Ehrinpreis MN: "Whipple's Disease", presented at Clinical-Pathological

Conference, Detroit, MI, March 23, 1994. 35. Ehrinpreis MN: "Malabsorption", presented at 14th Annual OHEP Intesine Internal

Medicine Review, Northfield Hilton, Troy, MI, June 9, 1994. 36. Ehrinpreis MN: "Helicobater Update - When and How to Treat", presented at

Update in Gastroenterology, Holy Cross Hospital, Detroit, Michigan, August 31, 1994.

37. Ehrinpreis MN: "Infectious Diseases of the Upper G.I. Tract", presented at Wayne

State University Symposium on Gastroenterology Advances: The Upper GI Tract, on, Mackinac Island, Michigan, September 8-11, 1994.

38. Ehrinpreis MN: "Nutritional Support-Progress & Problems", presented at

Gastroenterology Course, Bon Secours Hospital, Grosse Pointe, Michigan, October 6, 1994.

39. Ehrinpreis MN: "Drug-Induced Liver Disease", presented at Medicine Subspecialty

Conference, Oakwood Hospital, Dearborn, Michigan, February 7, 1995. 40. Ehrinpreis MN: "Esophageal Infections" Academic Workshop Leader, Michigan

Regional G.I. Consultants Conference, Traverse City, Michigan, March 31 - April 2, 1995.

41. Ehrinpreis MN: "Diagnosis and Management of PUD and Esophagitis", presented

at 15th Annual OHEP Internal Medicine Review, Northfield Hilton, Troy, Michigan, June 8, 1995.

42. Ehrinpreis MN: "Update on Pancreatitis", presented at Holy Cross Hospital GI

Symposium, Detroit, MI, August 3, 1995. 43. Ehrinpreis MN: "Acute Pancreatitis", presented at Providence Hospital Medical

Grand Rounds, Southfield, MI, October 26, 1995. 44. Ehrinpreis MN: "Implications of Helicobacter pylori Infection", Federal Pharmacists

Association Continuing Education, Ann Arbor, MI, January 25, 1996. 45. Ehrinpreis MN: "Helicobacter pylori", Oakwood Hospital, Dearborn, Michigan,

March 6, 1996. 46. Ehrinpreis MN: "Helicobacter pylori", Riverside Osteopathic Hospital, Trenton,

Michigan, March 7, 1996.

28 47. Ehrinpreis MN: “Peptic Ulcer Disease and Esophagitits”, presented at 16th Annual

OHEP Internal Medicine Review, Northfield Hilton, Troy, MI, June 13, 1996. 48. Ehrinpreis MN: “Advances in Total Parenteral Nutrition”, presented at the Update

in Gastroenterology, Holy Cross Hospital, Detrioit, MI, October 30, 1996. 49. Ehrinpreis MN: “Drug Induced Hepatitis”, presented at Liver Disease Symposium,

Macomb Hospital Center, Warren, MI, November 2, 1996. 50. Ehrinpreis MN: “Approach to GERD and PUD”, presented at Wayne State

University Gastroenterology Conference Special Lecture for OHEP Save 100 program, Detroit, MI, February 19, 1997.

51. Ehrinpreis MN: “Peptic Ulcer Disease and Esophagtitis” presented at 17th Annual

OHEP Internal Medicine Review, Northfield Hilton, Troy, MI, June 15, 1997. 52. Ehrinpreis MN: ACG Regional Postgraduate Course, Director and Moderator,

Ypsilanti Marriott, Ypsilanti, MI, June 21-22, 1997. 53. Ehrinpreis MN: “Helicobacter pylori Update” presented at 4th Annual

Gastroenterology Symposium, Holy Cross Hospital, Detroit, MI, August 27, 1997. 54. Ehrinpreis MN: “Post-radiation Rectal Bleeding” presented at Symposium on

Prostate Cancer, Karmanos Cancer Institute, Bloomfield Hills, MI, October 4, 1997. 55. Ehrinpreis MN: “Emergencies in Regional Enteritis”, presented at Wayne State

University Emergency Medicine Grand Rounds, Detroit Receiving Hospital, Detroit, MI, October 23, 1997.

56. Ehrinpreis MN: “Refractory Ascites,” presented at Gastroenterology & Hepatology:

Advances in Diagnosis and Treatment. Mackinac Island, MI. September 11, 1998 . 57. Ehrinpreis MN: "Update on Inflammatory Bowel Disease," presented at Medical

Grand Rounds, Wayne State University, Veterans Affairs Hospital, Detroit, MI, January 20, 1999.

58. Ehrinpreis MN: "Update on Pancreatitis," presented at Medical Grand Rounds Oakwood Hospital, Dearborn, MI. March 25, 1999. 59. Ehrinpreis MN: “Idiopathic Inflammatory Bowel Disease,” presented at 18th

annual OHEP Internal Medicine Review, Northfield Hilton, Troy, MI, June 10, 1999.

60. Ehrinpreis MN: "Future of Acid Suppression," presented at Medical Grand

Rounds, Memorial Medical Center, Ludington, MI. August 24, 1999. 61. Ehrinpreis MN: "Treatment of Chronic Hepatitis C," presented at Perspectives

on Hepatitis B & C for the Primary Care Physician, Novi Hilton, Novi, MI October 30,1999.

2962. Ehrinpreis MN: "Update on Hepatitis C," presented at the Phillipine Medical

Association Meeting, Westin, Southfield, MI. April 15, 2000. 63. Ehrinpreis MN: "Inflammatory Bowel Disease," presented at 2000 OHEP

Intensive Internal Medicine Board Review, Northfield Hilton, Troy, MI, June 8, 2000.

64. Ehrinpreis MN: "Enteral Nutrition, Including PEG-tube Feeding, " 7th Annual

Gastroenterology Symposium, St. John North East Community Hospital, Detroit, MI, September 27, 2000.

65. Ehrinpreis MN: “Inflammatory Bowel Disease,” presented at 2001 OHEP

Intensive Internal Medicine Board Review, Northfield Hilton, Troy, MI, June 14, 2001.

66. Ehrinpreis MN: "Helicobacter pylori Update including MALT

Lymphoma, " 8th Annual Gastroenterology Symposium, St. John North East Community Hospital, Detroit, MI, September 26, 2001.

67. Ehrinpreis MN: “Inflammatory Bowel Disease,” presented at 2002 OHEP

Intensive Internal Medicine Board Review, Northfield Hilton, Troy, MI, June 6, 2002.

68. Ehrinpreis MN: “Gastrointestinal Problems in Scleroderma,” presented at

Michigan Scleroderma Foundation Regional Meeting, Troy Marriott, Troy, MI, September 22, 2002.

69. Ehrinpreis MN: “Evaluation of Chronic Diarrhea,” presented at 9th Annual

Gastroenterology Symposium, St. John North East Community Hospital, Detroit, MI, September 25, 2002.

70. Ehrinpreis MN: “Update on Endoscopy: Video Capsule Endoscopy,”

presented at Medical Grand Rounds, Wayne State University, Detroit, MI, February 12, 2003.

71. Ehrinpreis MN: “Inflammatory Bowel Disease,” presented at 2003 OHEP

Intensive Internal Medicine Board Review, Beverly Hills, MI, June 5, 2003. 72. Ehrinpreis MN: “CPC: Developing GI Catastrophe,” presented at Medical Grand

Rounds, Sinai-Grace Hospital, Detroit, MI, October 23, 2003. 73. Ehrinpreis, MN: “Wireless Capsule Endoscopy,” presented at Wayne State

University Surgical Grand Rounds, Harper University Hospital, Detroit, MI, November 5, 2003.

74. Ehrinpreis MN: “Obscure Gastrointestinal Bleeding,” presented at

Gastroenterology and Hepatology: Advances in Diagnosis and Treatment, Mackinac Island, MI, September 11, 2004.

3075. Ehrinpreis MN: “Video Capsule Endoscopy,” presented at

Gastroenterology and Hepatology: Advances in Diagnosis and Treatment, Mackinac Island, MI, September 11, 2004.

76. Ehrinpreis MN: “Decision Making Related to Alternative Modes of Nutrition,”

presented at Ethics and Dysphagia, Rehabilitation Institute of Michigan, Detroit, October 9, 2004.

77. Ehrinpreis MN: “Inflammatory Bowel Disease,” “Esophageal Disorders,”

“‘Camera Pill’-Video Endoscopy,” presented at 5th Annual Update in Internal Medicine, Bay Harbor, MI, July 31, 2005.